- Home
- COCH vs VYNE Comparison
COCH vs VYNE Comparison
Compare COCH & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | VYNE |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 20.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | COCH | VYNE |
|---|---|---|
| Price | $0.69 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 380.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $16.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.29 |
| 52 Week High | $1.91 | $2.57 |
Technical Indicators
Market Signals| Indicator | COCH | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 54.73 |
| Support Level | $0.67 | $0.55 |
| Resistance Level | $0.73 | $0.60 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 63.84 | 65.16 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.